Luxturna Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for inherited retinal diseases, advancements in viral vector technology, early regulatory approvals for gene therapies, growth in rare disease research funding, increasing use of genetic diagnostics.

The growth in the forecast period can be attributed to expansion of gene therapy pipelines, rising investments in rare disease treatments, growing adoption of early genetic screening, increasing focus on long-term treatment outcomes, advancements in retinal delivery technologies. Major trends in the forecast period include increasing adoption of gene therapy treatments, rising focus on rare genetic eye disorders, growing investment in one-time curative therapies, expansion of precision ophthalmology solutions, enhanced integration of genetic screening and diagnosis.

The increasing prevalence of genetic eye disorders is expected to drive the growth of the Luxturna market in the coming years. Genetic eye disorders encompass a range of inherited conditions caused by gene mutations that affect the structure or function of the eyes, leading to visual impairments such as blindness or reduced vision. The rise in genetic eye disorders can be attributed to factors such as an increase in genetic mutations, aging populations, improved diagnostic technologies, and heightened awareness of hereditary conditions. Luxturna is a gene therapy used to treat inherited retinal diseases (IRDs) caused by mutations in the RPE65 gene, offering a potential cure by delivering a functional copy of the gene to restore vision. For example, in December 2023, the United Nations Development Programme (UNDP), a US-based government agency, reported that 19,551 individuals were diagnosed with vision impairments in 2022, with over 19,000 new diagnoses recorded in just the first seven months of 2023. Therefore, the rising prevalence of genetic eye disorders is contributing to the growth of the Luxturna market.

The rising healthcare expenditure is expected to drive the growth of the Luxturna market moving forward. Healthcare expenditure refers to the total amount spent on medical services, treatments, and products by governments, businesses, or individuals. The rise in healthcare expenditure can be attributed to factors such as aging populations, advancements in medical technology, the increasing prevalence of chronic diseases, and rising treatment costs. Increased healthcare expenditure supports Luxturna by enabling funding and improving access to advanced treatments like gene therapy for rare inherited retinal diseases, which are often expensive and require specialized care. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, marking a significant rise compared to the 0.9% growth seen in 2022. Therefore, the rise in healthcare expenditure is expected to fuel the growth of the Luxturna market.

A key trend in the Luxturna market is the conduct of real-world studies for its gene therapies, including adeno-associated virus (AAV) vector-based gene therapy, to build a reputation for transparency and dedication to patient outcomes. AAV vector-based gene therapy uses a modified virus to deliver therapeutic genes to cells, providing treatment for genetic diseases such as RPE65-related retinal dystrophy. For example, in April 2023, Spark Therapeutics, a US-based biotechnology company specializing in gene therapy treatments, presented real-world data for Luxturna (voretigene neparvovec), an AAV-based gene therapy for RPE65-related inherited retinal dystrophy (IRD), from an observational study of 8 Belgian patients at the ARVO 2023 Annual Meeting. Among 15 treated eyes, significant improvements in light sensitivity were observed 6 months post-treatment for red, blue, and white light, along with enhancements in the visual field (object III4). At 2 years post-treatment, Luxturna showed a mean change of -0.03 BCVA and -13.67 decibels in the full-field light sensitivity threshold. Regarding safety, 35% of patients experienced at least one ocular adverse event, with chorioretinal atrophic changes being the most common, reported in 13 cases.

Major companies operating in the luxturna market are F. Hoffmann-La Roche AG.

North America was the largest region in the luxturna market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luxturna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the luxturna market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the luxturna market by increasing costs of imported viral vectors, plasmid DNA, specialized manufacturing reagents, and ultra-cold storage logistics required for gene therapy production and distribution. North America and Europe are most affected due to dependence on cross-border sourcing of advanced gene therapy components, while Asia-Pacific faces higher barriers for technology transfer and manufacturing scale-up. These tariffs are raising overall therapy production costs and influencing reimbursement dynamics. However, they are also encouraging domestic gene therapy manufacturing, regional innovation hubs, and localized supply chains for advanced genomic medicines.

The luxturna market research report is one of a series of new reports that provides luxturna market statistics, including luxturna industry global market size, regional shares, competitors with a luxturna market share, detailed luxturna market segments, market trends and opportunities, and any further data you may need to thrive in the luxturna industry. This luxturna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Luxturna is a gene therapy treatment designed for patients with inherited retinal diseases caused by mutations in the RPE65 gene, which can result in vision loss and blindness. It works by delivering a functional copy of the RPE65 gene directly into retinal cells, enabling them to produce a protein essential for vision.

The primary indications for Luxturna include the treatment of RPE65-mediated inherited retinal disease and the management of vision loss. The treatment targets genetic mutations in the RPE65 gene that lead to progressive vision loss and blindness. Luxturna is delivered through a subretinal injection to provide a functional RPE65 gene, improving vision in eligible patients. The patient demographics for Luxturna include pediatric patients, adult patients, and those with an early diagnosis. Distribution channels for the therapy include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, with end users such as hospitals, ophthalmology clinics, specialty pharmacies, and research institutions.

The luxturna market consists of sales of diagnostic kits, ocular imaging devices, cell therapy products, ophthalmic surgical instruments, retinal imaging systems, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.